Alterity Therapeutics Limited (ATHE) Quote

ATHE under $2

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia

ATHE...............................https://stockcharts.com/h-sc/ui?s=ATHE&p=W&b=5&g=0&id=p86431144783

ATHE...................................https://stockcharts.com/h-sc/ui?s=ATHE&p=W&b=5&g=0&id=p86431144783

Phase 2 data due at AAN 2024 on April 14, 2024.

ATHE new 52 week low

Moron on ECN MEMX which is more often connected to Schwab, showing a little sellside size at $3.25, could be just some short being a fool trying to manipulate and keep it from breaking out to higher levels,they are most likely could end up getting squeezed out, or sorry they sold,and are just a fool.

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease
- ATH434 improved motor performance and general function –

- Webcast to be held this week to discuss new data and recent clinical progress –

MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that promising new data on the effect of ATH434 in a Parkinson’s disease primate model was presented at the Future of Parkinson’s Disease Conference 2023 that took place November 30 – December 3, 2023 in Austin, TX, USA.

The poster, entitled, “Effects of ATH434, a Clinical-Phase Small Molecule with Moderate Affinity for Iron, in Hemiparkinsonian Macaques”, was presented by Margaret Bradbury, PhD, Vice President of Research and Nonclinical Development at Alterity and collaborators from Vanderbilt University Medical Center and the Florey Institute of Neuroscience in Melbourne. The presentation demonstrated that ATH434 treatment improved motor performance and general function in monkeys with experimentally induced Parkinson’s disease. The favorable impact on Parkinson’s symptoms was associated with lower iron levels in the area of pathology. In addition, ATH434 treatment increased levels of synaptophysin, a protein marker that reflects functional connections between neurons.

David Stamler, M.D., Chief Executive Officer of Alterity, commented, “These new data are exciting because we have shown for the first time that ATH434 can reduce Parkinson’s symptoms in a higher order animal – the monkey. Importantly, the improvements in motor skills and general functioning that parallel human parkinsonism were associated with reductions in iron in affected brain regions, validating the approach we are using in our ongoing clinical trials. The data from this study improve our ability to predict clinical outcomes and increases our confidence level in our ongoing Phase 2 clinical trials in Multiple System Atrophy, a parkinsonian disorder with similar underlying pathology to Parkinson’s disease.”

The study compared daily oral doses of ATH434 (3 or 10 mg/kg) versus a vehicle (placebo) for 12-14 weeks after parkinsonian symptoms were evident. Monkeys were assessed with the Parkinson Behavior Rating Scale (PBRS) before, during and after dosing. At Week 12, all evaluable ATH434-treated monkeys (n=5) had stable or improving PBRS scores from Baseline to Week 12 whereas two of three vehicle-treated monkeys did not demonstrate improvement or worsened, as expected from the progressive nature of the Parkinson model. The components of the PBRS scale indicate that ATH434 reduced motor impairment and improved general functions such as posture, balance, activity, and gait. Favorable parkinsonian outcomes observed in each of the ATH434-treated monkeys were associated with lower iron in the right substantia nigra. In addition, monkeys with improved scores had higher right dorsal striatal synaptophysin, indicating functional recovery of nerve endings in this critical motor pathway.

The poster presentation can be accessed on the Published Scientific Research section of the Alterity website here.

Webcast details

AUSTRALIA PARTICIPANTS:
Date: Wednesday, 6 December 2023
Time: 9:00 a.m. AEDT (Sydney/Melbourne)


UNITED STATES PARTICIPANTS:
Date: Tuesday, 5 December 2023
Time: 2:00 p.m. Pacific Time
5:00 p.m. Eastern Time
Register for the Zoom webcast:
https://us02web.zoom.us/webinar/register/WN_9Lv1OWMtSSSqdJrRsKRiTA#/registration
Registration is required and dial in details will be sent directly upon registration.

About ATH434

Alterity’s lead candidate, ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce a-synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain. As an iron chaperone, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase 1 studies demonstrating the agent is well tolerated and achieved brain levels comparable to efficacious levels in animal

Wild

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease

she will soon enough my friend! athe volume is about to warm up big time come end of summer all imo!

soo oversold its not even funny, also float is dang near locked, shorts will pay dearly soon enough!!! athe!

more news should be coming in the next 2/3 months, add to your watch list and start scaling in!

remember folks, this ran hard around this time last year, news will see us in the 3/4 $ range now with the many potential developments that lie ahead, I've added close to 100k shares here last few days.

building myself a nice little position here folks! cant beat the current price!

From the sticky...



Alterity’s lead candidate, PBT434, is the first of a new generation of small molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. PBT434 has been shown to reduce abnormal accumulation of a-synuclein and tau proteins in animal models of disease by restoring normal iron balance in the brain. In this way, it has excellent potential to treat various forms of atypical Parkinsonism.


A more practical solution may be enabling natural autophagy, which AVXL Blarcamesine seems to do....

"reduce abnormal accumulation" via iron balance seems to be a step lower than that.

Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson’s and Alzheimer’s
https://alteritytherapeutics.com/investor-centre/news/2022/01/06/alterity-therapeutics-granted-new-us-patent-for-compounds-for-neurodegenerative-diseases-including-parkinsons-and-alzheimers/

Roar!

28 thousand revenues VS. over 70 million Market Cap. Only a study and phase 2... Many more to go and more money to be spent

$0.00 revenue per share and burning over $22,000,000 million on the regular

Profitability
Profit Margin 0.00%
Operating Margin (ttm) -56,493.91%...........

Management Effectiveness
Return on Assets (ttm) -38.31%
Return on Equity (ttm) -71.91%

Income Statement
Revenue (ttm) 28.15k
Revenue Per Share (ttm) 0.00
Quarterly Revenue Growth (yoy) 1.50%
Gross Profit (ttm) -352.92k
EBITDA -15.88M
Net Income Avi to Common (ttm) -16.38M
Diluted EPS (ttm) -0.6600

Cash Flow Statement
Operating Cash Flow (ttm) -14.18M
Levered Free Cash Flow (ttm) -8.64M

ATHE released news hasnt hit wires gap watch tomorrow ~> https://alteritytherapeutics.com/investor-centre/news/2021/07/15/new-publication-demonstrates-ath434-is-neuroprotective/

Chart -- ATHE

Testing the waters here. Close looked interesting. Maybe more upswing here tomorrow?

Added 2.08!

Wow float is locked

Look again

Off a patent? Nah

Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer's and

Looking like we got a RUNNER

I think many of US are lurking this and when something starts to happen we shall all pop to share. Tiiick tooock...

* * $ATHE Video Chart 04-21-2021 * *

Link to Video - click here to watch the technical chart video

$ATHE is screaming for the top as investors point to the company's ability to treat Parkinsonian diseases on social media. This low float stock could go far higher. https://cnafinance.com/alterity-therapeutics-athe-stock-is-rocketing-heres-why/

nobody home here but thought I'd post anyways. Back in recently with a starter of 1.62's. I believe this is the old prana (pran) which at one time had some nice big run ups. This can too :)

Vanderbilt university medical center is enrolling patients with MSA = Multiple System Astrophysics for Altering Therapeutics limited phase 2 clinical studies using ATH434 to treat patients with MSA Neurodegenerative disease. The patient enrollment started in October 2020. Vanderbilt Medical Center is one of the top 10 medical school university in the USA. Vanderbilt Medical center enroll millions of patients for clinical trial testing for company drug testing. The University has an excellent reputation for screaming patients for clinical trial studies and testing.

Looking forward to the company addressing the share holders tomorrow. Will love to see a big spike in share price during pre market

* * $ATHE Video Chart 11-16-2020 * *

Link to Video - click here to watch the technical chart video

GREAT ATHE NEWS. WATCHING SOLO AND GTEC.

ATHE news !


Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has today announced the allowance of a new composition of matter patent by the United States Patent and Trademark Office (USPTO). The new patent is the product of in-house discovery research and is central to Alterity’s next generation drug development portfolio focussed on neurodegenerative diseases.

The patent, entitled “Compounds for and Methods of Treating Diseases” (Application No. 16/818,641), covers more than 150 novel pharmaceutical compositions that are designed to redistribute the labile iron implicated in Parkinson’s disease, Alzheimer’s disease and other neurodegenerative conditions. The patent, which was filed in March of 2020, underwent prioritized examination by the USPTO.

Alterity’s strategy is based on the hypothesis that its therapeutics can disrupt the underlying pathology of neurodegenerative conditions in which labile iron is implicated in disease pathology. This includes Parkinsonian disorders such as Parkinson’s disease and Multiple System Atrophy, as well as Alzheimer’s disease.

The patent confers on Alterity 20 years of exclusivity, providing a strong basis for continued drug development and commercialization and new compound identification within its extensive drug discovery library to target important neurodegenerative diseases.

This new patent will support the expansion of Alterity’s drug development portfolio. Its most advanced compound, ATH434, currently in clinical development has a favourable safety and pharmacokinetic profile, achieving drug concentrations at the site of action that met or exceeded those associated with efficacy in animal models of Parkinson’s disease and its first clinical target, Multiple System Atrophy.

Alterity’s Chairman and CEO, Mr Geoffrey Kempler said, “This broad patent establishes an excellent foundation for the company to pursue multiple therapeutics across a spectrum of neurodegenerative disease.”

“There is a growing clinical and scientific focus on the implication of elevated iron in the brain of people with neurodegenerative disease. Alterity has been at the forefront of research and drug development in this area, and we have significant research to support our current and future drug development efforts.”

“This patent allows us to fully prosecute these opportunities with confidence in the coming years to address some of the most devastating brain diseases which currently have few or no treatment options.

In addition to the US, the company is pursuing patent protection in other jurisdictions.

* * $ATHE Video Chart 08-04-2020 * *

Link to Video - click here to watch the technical chart video

MC is only about 67 millions and I anticipate it will be over $100 millions soon.

Nice

I bought 5000 shares today and plan to hold until phase III data out. If the drug is validated in phase III, one of the big pharms will buy out.

I’m loading more looks good

The drug candidate has a huge potential and SP can easily be over $10.

Let’s take her to $10

Looking sweet here

thanks, 18.1 M is still very small OS

TD shows 18.1. Profit takers. Watch close on these. The news looks great.

$ATHE

OTC is showing 14M OS is that correct?

Nice. Looks good here. Imho. Have a great day!

$ATHE